U.S. flag

An official website of the United States government

Format

Send to:

Choose Destination

Refractory Lung Non-Squamous Non-Small Cell Carcinoma

MedGen UID:
1779624
•Concept ID:
C5447476
•
Neoplastic Process

Definition

Non-squamous non-small cell lung carcinoma that is resistant to treatment. [from NCI]

Term Hierarchy

CClinical test,  RResearch test,  OOMIM,  GGeneReviews,  VClinVar  
  • CROGVRefractory Lung Non-Squamous Non-Small Cell Carcinoma

Recent clinical studies

Etiology

Trastuzumab deruxtecan in patients with metastatic non-small-cell lung cancer (DESTINY-Lung01): primary results of the HER2-overexpressing cohorts from a single-arm, phase 2 trial.
Smit EF, Felip E, Uprety D, Nagasaka M, Nakagawa K, Paz-Ares Rodríguez L, Pacheco JM, Li BT, Planchard D, Baik C, Goto Y, Murakami H, Saltos A, Pereira K, Taguchi A, Cheng Y, Yan Q, Feng W, Tsuchihashi Z, Jänne PA
Lancet Oncol 2024 Apr;25(4):439-454. doi: 10.1016/S1470-2045(24)00064-0. PMID: 38547891
IFCT-1502 CLINIVO: real-world evidence of long-term survival with nivolumab in a nationwide cohort of patients with advanced non-small-cell lung cancer.
Molinier O, Besse B, Barlesi F, Audigier-Valette C, Friard S, Monnet I, Jeannin G, Mazières J, Cadranel J, Hureaux J, Hilgers W, Quoix E, Coudert B, Moro-Sibilot D, Fauchon E, Westeel V, Brun P, Langlais A, Morin F, Souquet PJ, Girard N
ESMO Open 2022 Feb;7(1):100353. Epub 2021 Dec 23 doi: 10.1016/j.esmoop.2021.100353. PMID: 34953398Free PMC Article
Multicenter phase II trial of nintedanib plus docetaxel in second-line treatment in advanced non-squamous non-small cell lung cancer patients refractory to first-line platin-based chemotherapy (REFRACT GFPC 02-15 study).
Auliac JB, Monnet I, Bizieux A, Greillier L, Geier M, Falchero L, Le Garff G, Lamy R, Guisier F, Ricordel C, Chouaid C, Vergnenegre A; REFRACT GFPC 02-15 investigators
Lung Cancer 2021 Nov;161:122-127. Epub 2021 Sep 20 doi: 10.1016/j.lungcan.2021.09.007. PMID: 34583220
Phase 1, pharmacogenomic, dose-expansion study of pegargiminase plus pemetrexed and cisplatin in patients with ASS1-deficient non-squamous non-small cell lung cancer.
Szlosarek PW, Wimalasingham AG, Phillips MM, Hall PE, Chan PY, Conibear J, Lim L, Rashid S, Steele J, Wells P, Shiu CF, Kuo CL, Feng X, Johnston A, Bomalaski J, Ellis S, Grantham M, Sheaff M
Cancer Med 2021 Oct;10(19):6642-6652. Epub 2021 Aug 12 doi: 10.1002/cam4.4196. PMID: 34382365Free PMC Article
Analysis of bevacizumab treatments and metastatic sites of lung cancer.
Sato H, Nagashima H, Akiyama M, Ito T, Hashimoto T, Saikawa H, Utsumi Y, Maemondo M
Cancer Treat Res Commun 2021;26:100290. Epub 2020 Dec 26 doi: 10.1016/j.ctarc.2020.100290. PMID: 33373900

Diagnosis

Real-world data on EGFR/ALK gene status and first-line targeted therapy rate in newly diagnosed advanced non-small cell lung cancer patients in Northern China: A prospective observational study.
Liang H, Song X, Zhang Y, Zhang S, Li F, Fang J, Li J, Liang L, Nie L, Ma K, Zhang L, Wang X, Xu J, Wei Y, Wang J, Song Q, Tian G, Mu Y, Gu Y, Yang L, Sun P, Zhong W, Zhao J, Xu Y, Chen M, Wang M
Thorac Cancer 2019 Jul;10(7):1521-1532. Epub 2019 May 29 doi: 10.1111/1759-7714.13090. PMID: 31144459Free PMC Article
The present and future burden of previously treated advanced non-small cell lung cancer (NSCLC) by histology and line of therapy in France, Germany, Italy, and Spain: model-based predictions.
Campbell D, O'Day K, Hertel N, Penrod JR, Manley Daumont M, Lees M
Popul Health Metr 2018 Nov 26;16(1):17. doi: 10.1186/s12963-018-0174-4. PMID: 30477516Free PMC Article

Therapy

Trastuzumab deruxtecan in patients with metastatic non-small-cell lung cancer (DESTINY-Lung01): primary results of the HER2-overexpressing cohorts from a single-arm, phase 2 trial.
Smit EF, Felip E, Uprety D, Nagasaka M, Nakagawa K, Paz-Ares Rodríguez L, Pacheco JM, Li BT, Planchard D, Baik C, Goto Y, Murakami H, Saltos A, Pereira K, Taguchi A, Cheng Y, Yan Q, Feng W, Tsuchihashi Z, Jänne PA
Lancet Oncol 2024 Apr;25(4):439-454. doi: 10.1016/S1470-2045(24)00064-0. PMID: 38547891
SAFFRON-103: a phase 1b study of the safety and efficacy of sitravatinib combined with tislelizumab in patients with locally advanced or metastatic non-small cell lung cancer.
Zhao J, Yu X, Huang D, Ma Z, Gao B, Cui J, Chu Q, Zhou Q, Sun M, Day D, Wu J, Pan H, Wang L, Voskoboynik M, Wang Z, Liu Y, Li H, Zhang J, Peng Y, Wu YL
J Immunother Cancer 2023 Feb;11(2) doi: 10.1136/jitc-2022-006055. PMID: 36808075Free PMC Article
Multicenter phase II trial of nintedanib plus docetaxel in second-line treatment in advanced non-squamous non-small cell lung cancer patients refractory to first-line platin-based chemotherapy (REFRACT GFPC 02-15 study).
Auliac JB, Monnet I, Bizieux A, Greillier L, Geier M, Falchero L, Le Garff G, Lamy R, Guisier F, Ricordel C, Chouaid C, Vergnenegre A; REFRACT GFPC 02-15 investigators
Lung Cancer 2021 Nov;161:122-127. Epub 2021 Sep 20 doi: 10.1016/j.lungcan.2021.09.007. PMID: 34583220
Analysis of bevacizumab treatments and metastatic sites of lung cancer.
Sato H, Nagashima H, Akiyama M, Ito T, Hashimoto T, Saikawa H, Utsumi Y, Maemondo M
Cancer Treat Res Commun 2021;26:100290. Epub 2020 Dec 26 doi: 10.1016/j.ctarc.2020.100290. PMID: 33373900
Camrelizumab: First Global Approval.
Markham A, Keam SJ
Drugs 2019 Aug;79(12):1355-1361. doi: 10.1007/s40265-019-01167-0. PMID: 31313098

Prognosis

IFCT-1502 CLINIVO: real-world evidence of long-term survival with nivolumab in a nationwide cohort of patients with advanced non-small-cell lung cancer.
Molinier O, Besse B, Barlesi F, Audigier-Valette C, Friard S, Monnet I, Jeannin G, Mazières J, Cadranel J, Hureaux J, Hilgers W, Quoix E, Coudert B, Moro-Sibilot D, Fauchon E, Westeel V, Brun P, Langlais A, Morin F, Souquet PJ, Girard N
ESMO Open 2022 Feb;7(1):100353. Epub 2021 Dec 23 doi: 10.1016/j.esmoop.2021.100353. PMID: 34953398Free PMC Article
Multicenter phase II trial of nintedanib plus docetaxel in second-line treatment in advanced non-squamous non-small cell lung cancer patients refractory to first-line platin-based chemotherapy (REFRACT GFPC 02-15 study).
Auliac JB, Monnet I, Bizieux A, Greillier L, Geier M, Falchero L, Le Garff G, Lamy R, Guisier F, Ricordel C, Chouaid C, Vergnenegre A; REFRACT GFPC 02-15 investigators
Lung Cancer 2021 Nov;161:122-127. Epub 2021 Sep 20 doi: 10.1016/j.lungcan.2021.09.007. PMID: 34583220
Analysis of bevacizumab treatments and metastatic sites of lung cancer.
Sato H, Nagashima H, Akiyama M, Ito T, Hashimoto T, Saikawa H, Utsumi Y, Maemondo M
Cancer Treat Res Commun 2021;26:100290. Epub 2020 Dec 26 doi: 10.1016/j.ctarc.2020.100290. PMID: 33373900
Real-world data on EGFR/ALK gene status and first-line targeted therapy rate in newly diagnosed advanced non-small cell lung cancer patients in Northern China: A prospective observational study.
Liang H, Song X, Zhang Y, Zhang S, Li F, Fang J, Li J, Liang L, Nie L, Ma K, Zhang L, Wang X, Xu J, Wei Y, Wang J, Song Q, Tian G, Mu Y, Gu Y, Yang L, Sun P, Zhong W, Zhao J, Xu Y, Chen M, Wang M
Thorac Cancer 2019 Jul;10(7):1521-1532. Epub 2019 May 29 doi: 10.1111/1759-7714.13090. PMID: 31144459Free PMC Article
The role of pemetrexed in advanced non small-cell lung cancer: special focus on pharmacology and mechanism of action.
Joerger M, Omlin A, Cerny T, Früh M
Curr Drug Targets 2010 Jan;11(1):37-47. doi: 10.2174/138945010790030974. PMID: 19839929

Clinical prediction guides

Trastuzumab deruxtecan in patients with metastatic non-small-cell lung cancer (DESTINY-Lung01): primary results of the HER2-overexpressing cohorts from a single-arm, phase 2 trial.
Smit EF, Felip E, Uprety D, Nagasaka M, Nakagawa K, Paz-Ares Rodríguez L, Pacheco JM, Li BT, Planchard D, Baik C, Goto Y, Murakami H, Saltos A, Pereira K, Taguchi A, Cheng Y, Yan Q, Feng W, Tsuchihashi Z, Jänne PA
Lancet Oncol 2024 Apr;25(4):439-454. doi: 10.1016/S1470-2045(24)00064-0. PMID: 38547891
SAFFRON-103: a phase 1b study of the safety and efficacy of sitravatinib combined with tislelizumab in patients with locally advanced or metastatic non-small cell lung cancer.
Zhao J, Yu X, Huang D, Ma Z, Gao B, Cui J, Chu Q, Zhou Q, Sun M, Day D, Wu J, Pan H, Wang L, Voskoboynik M, Wang Z, Liu Y, Li H, Zhang J, Peng Y, Wu YL
J Immunother Cancer 2023 Feb;11(2) doi: 10.1136/jitc-2022-006055. PMID: 36808075Free PMC Article
Real-world data on EGFR/ALK gene status and first-line targeted therapy rate in newly diagnosed advanced non-small cell lung cancer patients in Northern China: A prospective observational study.
Liang H, Song X, Zhang Y, Zhang S, Li F, Fang J, Li J, Liang L, Nie L, Ma K, Zhang L, Wang X, Xu J, Wei Y, Wang J, Song Q, Tian G, Mu Y, Gu Y, Yang L, Sun P, Zhong W, Zhao J, Xu Y, Chen M, Wang M
Thorac Cancer 2019 Jul;10(7):1521-1532. Epub 2019 May 29 doi: 10.1111/1759-7714.13090. PMID: 31144459Free PMC Article
The role of pemetrexed in advanced non small-cell lung cancer: special focus on pharmacology and mechanism of action.
Joerger M, Omlin A, Cerny T, Früh M
Curr Drug Targets 2010 Jan;11(1):37-47. doi: 10.2174/138945010790030974. PMID: 19839929
Investigating the potential of bevacizumab in other indications: metastatic renal cell, non-small cell lung, pancreatic and breast cancer.
de Gramont A, Van Cutsem E
Oncology 2005;69 Suppl 3:46-56. Epub 2005 Nov 21 doi: 10.1159/000088483. PMID: 16301835

Supplemental Content

Table of contents

    Practice guidelines

    • Bookshelf
      See practice and clinical guidelines in NCBI Bookshelf. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.

    Related information

    • PMC Articles
      Related information in PubMed Central Links
    • PubMed
      Related literature resources in PubMed

    Recent activity

    Clear Turn Off Turn On

    Your browsing activity is empty.

    Activity recording is turned off.

    Turn recording back on

    See more...